OS
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Adriana Balduzzi, Evgenia Glogova, Christina Peters, Petr Sedlacek, Jean-Hugues Dalle, Franco Locatelli, Roland Meisel, Birgit Burkhardt, Jochen Buechner, Jacek Wachowiak, Marc Bierings, Raquel Staciuk, Stelios Graphakos, Tayfun Güngör, Akif Yesilipek, Peter Svec, Julia Palma, Gergely Krivan, Cristina Diaz-de-Heredia, Francesca Limido, Marc Ansari, Krzysztof Kalwak, Peter Bader, Marianne Ifversen
Haematologica 111(1) 122-134
In the randomized cohort of the international phase-III FORUM trial, which showed the superiority of total-body irradiation (TBI) over chemotherapy-based conditioning prior to hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL), type of conditioning and remission phase, but not pre-HSCT minimal residual disease (MRD), were associated with outcome. We report the impact of MRD within the extended FORUM cohort. Patients (N=1,014) aged 4-21 years old, transplanted from a matched donor who had ≥1 MRD measurement prior to and/or 100 days and/or one year after HSCT were eligible. A threshold of 0.01% defined MRD positivity versus negativity. Prior to HSCT, 21% of patients were MRDpos. Three-year event-free survival (EFS) was 0.73 and 0.59 (P<0.001), and 3-year cumulative incidence of relapse (CIR) was 0.20 and 0.33 (P<0.001) in MRDneg and MRDpos patients, respectively. The level of MRD positivity pre-HSCT (<0.1% vs. ≥0.1%) did not significantly affect outcome. Pre-HSCT MRDneg and TBI/etoposide conditioning were associated with a 2-fold lower risk of relapse, whereas MRDpos had a 2-fold higher risk of any failure and/or death. No detrimental effect of MRDpos pre-HSCT could be demonstrated in patients with T-cell ALL. MRDpos versus MRDneg patients at day 100 had an EFS of 0.47 versus 0.77 (P<0.001) and a CIR of 0.51 versus 0.17 (P<0.001), respectively, but post-HSCT MRDpos did not necessarily imply relapse. In conclusion, the MRD status pre-HSCT and at day 100 post-HSCT was a strong prognostic factor for children transplanted for ALL in the extended FORUM cohort.
2 个 Figure · 16 个 KM 面板
Figure 2. Outcome according to minimal residual disease status at the time of hematopoietic stem cell transplantation . Overall survival (OS) (A), event-free survival (EFS) (B), cumulative incidence of relapse (CIR) (C), and transplant-related mortality (TRM) (D). EFS (E) and CIR (F) for the total body irradiation/etoposide (TBI/VP16) subgroup. EFS (G) and CIR (H) for the chemo-conditioning subgroup. HSCT: hematopoietic stem cell transplantation; MRD: minimal residual disease; PCR: polymerase chain reaction; pos: positive; SE: Standard Error; TBI: total body irradiation; VP16: etoposide.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel C
Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel D
Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel E
Panel E 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel F
Panel F 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel G
Panel G 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel H
Panel H 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. Outcome by minimal residual disease status at the time of hematopoietic stem cell transplantation according to immunophenotype. Overall survival (OS) (A), event-free survival (EFS) (B), cumulative incidence of relapse (CIR) (C), and transplant-related mortality (TRM) (D) for patients affected with B-lineage acute lymphoblastic leukemia (ALL). OS (E), EFS (F), CIR (G), and TRM (H) for those affected with T-lineage ALL. HSCT: hematopoietic stem cell transplantation; MRD: minimal residual disease; PCR: polymerase chain reaction; pos: positive; SE: Standard Error; TBI: total body irradiation; VP16: etoposide.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D
Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel E
Panel E 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel F
Panel F 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel G
Panel G 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel H
Panel H 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。